Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kaur, Harpreet ^a   Jajodia, Ajay ^a   Grover, Sandeep ^a   Baghel, Ruchi ^a   Gupta, Meenal ^a   Jain, Sanjeev ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CLOZAPINE; DOPAMINE TRANSPORTER; FLUPENTIXOL; FLUPHENAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RGS4 PROTEIN; RISPERIDONE; SULPIRIDE; ZIPRASIDONE; PHOSPHOTRANSFERASE; PIP4K2A PROTEIN, HUMAN;

ADULT; ARTICLE; BDNF GENE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; PI4KA GENE; PIP4K2A GENE; RGS4 GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A3 GENE; CASE CONTROL STUDY; GENETICS; NUCLEOTIDE SEQUENCE; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904265814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102556     Document Type: Article

References (69)

1. Zandi PP, Judy JT (2010) The promise and reality of pharmacogenetics in psychiatry. Clin Lab Med 30: 931-974.
2. Kirov G, O'Donovan MC, Owen MJ (2005) Finding schizophrenia genes. J Clin Invest 115: 1440-1448. (Pubitemid 40814648)
3. Chen L, Ascher Svanum H, Stauffer V, Kinon BJ, Kollack Walker S, et al. (2009) Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 113: 34-40.
4. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, et al. (2010) BDNF function and intracellular signaling in neurons. Histol Histopathol 25: 237-258.
5. Sakata K, Duke SM (2014) Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus. Neuroscience 260: 265-75.
6. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P (2001) The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11: 449-455. (Pubitemid 33026519)
7. Riddle EL, Fleckenstein AE, Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7: E847-851.
8. Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG (2006) Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets 5: 45-56. (Pubitemid 43796627)
9. Sjoholm H, Bratlid T, Sundsfjord J (2004) 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) 173: 27-31. (Pubitemid 38591143)
10. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001) Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6: 293-301. (Pubitemid 32275674)
11. Lipska BK, Mitkus S, Caruso M, Hyde TM, Chen J, et al. (2006) RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Hum Mol Genet 15: 2804-2812. (Pubitemid 44400407)
12. Conn PJ, Sanders Bush E (1986) Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci 6: 3669-3675. (Pubitemid 17208550)
13. Undie AS, Friedman E (1992) Aging-induced decrease in dopaminergic-stimulated phosphoinositide metabolism in rat brain. Neurobiol Aging 13: 505-511.
14. Jungerius BJ, Hoogendoorn ML, Bakker SC, Van't Slot R, Bardoel AF, et al. (2008) An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol Psychiatry 13: 1060-1068.
15. Thiselton DL, Maher BS, Webb BT, Bigdeli TB, O'Neill FA, et al. (2010) Association analysis of the PIP4K2A gene on chromosome 10p12 and schizophrenia in the Irish study of high density schizophrenia families (ISHDSF) and the Irish case-control study of schizophrenia (ICCSS). Am J Med Genet B Neuropsychiatr Genet 153B: 323-331.
16. Clarke JH, Irvine RF (2013) Enzyme activity of the PIP4K2A gene product polymorphism that is implicated in schizophrenia. Psychopharmacology (Berl) 230: 329-331.
17. Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, et al. (2006) Evidence for association of DNA sequence variants in the phosphatidylinositol-4- phosphate 5-kinase II alpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 11: 837-846. (Pubitemid 44299105)
18. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, et al. (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29: 233-237. (Pubitemid 32952665)
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229. (Pubitemid 34680308)
20. Akey J, Jin L, Xiong M (2001) Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 9: 291-300. (Pubitemid 32366698)
21. Kamatani N, Sekine A, Kitamoto T, Iida A, Saito S, et al. (2004) Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed with haplotype-tagging SNPs. Am J Hum Genet 75: 190-203. (Pubitemid 38943863)
22. Lin S, Chakravarti A, Cutler DJ (2004) Exhaustive allelic transmission disequilibrium tests as a new approach to genome-wide association studies. Nat Genet 36: 1181-1188. (Pubitemid 41288967)
23. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223. (Pubitemid 41568704)
24. Dominguez E, Loza MI, Padin F, Gesteira A, Paz E, et al. (2007) Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population. Schizophr Res 90: 123-129. (Pubitemid 46201673)
25. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al. (1990) SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47: 589-593. (Pubitemid 20189971)
26. McGuffin P (2004) Nature and nurture interplay: schizophrenia. Psychiatr Prax 31 Suppl 2: S189-193.
27. Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, et al. (2009) Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 10: 385-397.
28. Pritchard JK, Rosenberg NA (1999) Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65: 220-228. (Pubitemid 30470467)
29. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P (2000) Association mapping in structured populations. Am J Hum Genet 67: 170-181. (Pubitemid 30481554)
30. Abdulla MA, Ahmed I, Assawamakin A, Bhak J, Brahmachari SK, et al. (2009) Mapping human genetic diversity in Asia. Science 326: 1541-1545.
31. Jha P, Sinha S, Kanchan K, Qidwai T, Narang A, et al. (2012) Deletion of the APOBEC3B gene strongly impacts susceptibility to falciparum malaria. Infect Genet Evol 12: 142-148.
32. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945-959. (Pubitemid 30397141)
33. Roden DM, George AL Jr (2002) The genetic basis of variability in drug responses. Nat Rev Drug Discov 1: 37-44. (Pubitemid 37361402)
34. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, et al. (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22: 1790-1797.
35. Ward LD, Kellis M (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40: D930-934.
36. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
37. Purcell S, Neale B, Todd Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575. (Pubitemid 47330214)
38. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. (Pubitemid 40202029)
39. Dupont WD (1988) Power calculations for matched case-control studies. Biometrics 44: 1157-1168.
40. StephensM, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989. (Pubitemid 32289743)
41. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, et al. (2006) A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241: 252-261. (Pubitemid 43993963)
42. Huang N, Chelliah Y, Shan Y, Taylor CA, Yoo SH, et al. (2012) Crystal structure of the heterodimeric CLOCK:BMAL1 transcriptional activator complex. Science 337: 189-194.
43. Fedorenko O, Strutz Seebohm N, Henrion U, Ureche ON, Lang F, et al. (2008) A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels. Psychopharmacology (Berl) 199: 47-54.
44. Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. Nature 341: 197-205. (Pubitemid 19231718)
45. Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614.
46. Rameh LE, Tolias KF, Duckworth BC, Cantley LC (1997) A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature 390: 192-196. (Pubitemid 27507991)
47. Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443: 651-657. (Pubitemid 44564702)
48. Hallcher LM, Sherman WR (1980) The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 255: 10896-10901. (Pubitemid 11171746)
49. Fedorenko O, Tang C, Sopjani M, Foller M, Gehring EM, et al. (2009) PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. Psychopharmacology (Berl) 206: 429-435.
50. Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, et al. (2007) The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 6: 113-119. (Pubitemid 46328582)
51. Saggers Gray L, Heriani H, Handoko HY, Irmansyah I, Kusumawardhani AA, et al. (2008) Association of PIP5K2A with schizophrenia: a study in an indonesian family sample. Am J Med Genet B Neuropsychiatr Genet 147B: 1310-1313.
52. Clark AG (2004) The role of haplotypes in candidate gene studies. Genet Epidemiol 27: 321-333.
53. He Z, Li Z, Shi Y, Tang W, Huang K, et al. (2007) The PIP5K2A gene and schizophrenia in the Chinese population-a case-control study. Schizophr Res 94: 359-365. (Pubitemid 47031592)
54. Fedorenko O, Rudikov EV, Gavrilova VA, Boiarko EG, Semke AV, et al. (2013) Association of (N251S)-PIP5K2A with schizophrenic disorders: a study of the Russian population of Siberia. Zh Nevrol Psikhiatr Im S S Korsakova 113: 58-61.
55. Jamra RA, Klein K, Villela AW, Becker T, Schulze TG, et al. (2006) Association study between genetic variants at the PIP5K2A gene locus and schizophrenia and bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 141B: 663-665. (Pubitemid 44434668)
56. Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, et al. (2005) Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 111: 220-231. (Pubitemid 40342191)
57. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, et al. (2005) Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm 112: 885-890. (Pubitemid 40869077)
58. Xu M, Li S, Xing Q, Gao R, Feng G, et al. (2010) Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur J Hum Genet 18: 707-712.
59. Watanabe Y, Nunokawa A, Someya T (2013) Association of the BDNF C270T polymorphism with schizophrenia: updated meta-analysis. Psychiatry Clin Neurosci 67: 123-125.
60. Dayem Ullah AZ, Lemoine NR, Chelala C (2012) SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). Nucleic Acids Res 40: W65-70.
61. Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, et al. (2012) The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 39: 96-101.
62. Pae CU, Chiesa A, Porcelli S, Han C, Patkar AA, et al. (2012) Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology 65: 1-11.
63. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2011) Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 16: 960-972.
64. Luoni A, Fumagalli F, Racagni G, Riva MA (2014) Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. Pharmacol Res 80C: 1-8.
65. Huang SY, Chen HK, Ma KH, Shy MJ, Chen JH, et al. (2010) Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese. Schizophr Res 116: 68-74.
66. Mas S, Bernardo M, Parellada E, Garcia Rizo C, Gasso P, et al. (2009) ARVCF single marker and haplotypic association with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33: 1064-1069.
67. Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, et al. (2008) A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet 17: 747-758. (Pubitemid 351292263)
68. Jeong SH, Joo EJ, Ahn YM, Kim YS (2004) Association study of dopamine transporter gene and schizophrenia in Korean population using multiple single nucleotide polymorphism markers. Prog Neuropsychopharmacol Biol Psychiatry 28: 975-983. (Pubitemid 39223353)
69. Gibson G (2012) Rare and common variants: twenty arguments. Nat Rev Genet 13: 135-145.